Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.

CONCLUSION: Determination of the HLA-Cw6 status for secukinumab therapy is unnecessary, as it is highly effective regardless of the HLA-Cw6 status. This article is protected by copyright. All rights reserved. PMID: 29704432 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29704432?dopt=Abstract

Source: The British Journal of Dermatology - April 28, 2018 Category: Dermatology Authors: Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G, SUPREME study group Tags: Br J Dermatol Source Type: research